Drug Profile
THR 18
Alternative Names: Plasminogen activator inhibitor-1-derived 18-mer peptide; THR-18Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Hadassah Medical Organization
- Developer D-Pharm; Thrombotech
- Class Antithrombotics; Neuroprotectants; Peptides
- Mechanism of Action Plasminogen activator inhibitor-1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stroke
- No development reported Myocardial infarction; Pulmonary embolism
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Myocardial-infarction in Israel (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Pulmonary-embolism in Israel (IV, Infusion)
- 16 Nov 2015 Phase-II clinical trials in Stroke (Combination therapy) in Moldova (IV) (NCT02572336 )